ORCA – Online Research @ Cardiff



This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/150114/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Schepelmann, Martin, Ranieri, Marianna, Lopez-Fernandez, Irene, Webberley,
Thomas S., Brennan, Sarah C., Yarova, Polina L., Graca, Joao, Hanif, Umar-Khetaab,
Müller, Christian, Manhardt, Teresa, Salzmann, Martina, Quasnichka, Helen, Price,
Sally A., Ward, Donald T., Gilbert, Thierry, Matchkov, Vladimir V., Fenton, Robert A.,
Herberger, Amanda, Hwong, Jenna, Santa Maria, Christian, Tu, Chia-Ling, Kallay,
Enikö, Valenti, Giovanna, Chang, Wenhan and Riccardi, Daniela 2022. Impaired
mineral ion metabolism in a mouse model of targeted calcium-sensing receptor
(CaSR) deletion from vascular smooth muscle cells. Journal of the American Society
of Nephrology 33 (7), pp. 1323-1340. 10.1681/ASN.2021040585

Publishers page: http://dx.doi.org/10.1681/ASN.2021040585

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Impaired mineral ion metabolism in a mouse model of targeted calciumsensing receptor (CaSR) deletion from vascular smooth muscle cells.

Accepted author manuscript (not proofed, not copyedited; not updated).

The proofed and copyedited published version can be found at:

https://doi.org/10.1681/ASN.2021040585

https://jasn.asnjournals.org/content/early/2022/05/17/ASN.2021040585

1	Impaired mineral ion me	tabolism in a mouse model of						
2	targeted calcium-sensing	receptor (CaSR) deletion from						
3	vascular smo	ooth muscle cells						
4								
5	Martin Schepelmann ^{1,2} , Marianna Ranieri ³ , Irene Lo	ppez-Fernandez ¹ , Thomas S. Webberley ¹ , Sarah C. Brennan ^{1,4} ,						
6								
7	Salzmann ² , Helen Quasnichka ¹ , Sally A. Price ⁶ , Donald T. Ward ⁷ , Thierry Gilbert ⁸ , Vladimir V. Matchkov ⁹ , Rober							
8	A. Fenton ⁹ , Amanda Herberger ¹⁰ , Jenna Hwong ¹⁰ , Christian Santa Maria ¹⁰ , Chia-Ling Tu ¹⁰ , Enikö Kallay ²							
9	Giovanna Valenti ³ , Wenhan Chang ¹⁰ and Daniela Riccardi ¹ .							
10								
11	1 School of Biosciences, Cardiff University, United Kingdom							
12	2 Institute of Pathophysiology and Allergy Research, Medical Ur	niversity of Vienna, Austria						
13	3 Department of Biosciences, Biotechnologies and Biopharmaceu	atics, University of Bari, Italy						
14	4 Charles Perkins Centre, University of Sydney, NSW 2006, Australia							
15	5 Translational & Clinical Research Institute, Newcastle University Medical School, Newcastle upon Tyne, UK							
16	6 AstraZeneca, Macclesfield, Cheshire, United Kingdom							
17	7 Division of Diabetes, Endocrinology & Gastroenterology, Univ	versity of Manchester, Manchester, UK						
18	8 Centre for Developmental Biology, University Paul Sabatier, T	oulouse, FR						
19	9 Department of Biomedicine, Aarhus University, Aarhus 8000, I	DK						
20	10 Department of Medicine, University of California, San Francisco, CA, USA							
21								
22	Running title: Mineral ion dyshomeostasis	in VSMC-CaSR knockout mice						
23 24	Address correspondence to:							
25 26	Wenhan Chang, PhD University of California San Francisco	Martin Schepelmann, PhD Institute of Pathophysiology and Allergy Research						
27	Medical University of Vienna							
28	28 San Francisco CA 94158, USA Währinger Gürtel 18-20, Leitstelle 3Q							
29 30	Wenhan.Chang@ucsf.edu	Phone: (+43) 1 40400 51230						
31 32	Daniela Riccardi, PhD	martin.schepelmann@meduniwien.ac.at						
33	School of Biosciences							
34 35	The Sir Martin Evans Building, Cardiff University Cardiff CF10 3AX, United Kingdom							
36	Phone: (44) (0) 29 208 79132							
37	riccardi@cardiff.ac.uk							

38 Significance statement

39 Chronic kidney disease (CKD) is associated with increased risk of mortality. In CKD, calcium 40 and phosphate dyshomeostasis are associated with altered expression of the calcium-sensing 41 receptor (CaSR) in the parathyroid glands and the kidney. The CaSR is also present in the 42 vasculature, but its contribution to total body mineral ion homeostasis is unknown. Here we 43 show that selective CaSR ablation from vascular smooth muscle cells (VSMC) leads to 44 profound mineral ion imbalance in mice. These results demonstrate a hitherto undiscovered 45 mode of mineral ion regulation outside the parathyroid glands and the kidneys. Alterations in 46 VSMC-CaSR expression and activity would be expected to contribute to mineral ion imbalance in 47 CKD.

48 Abstract

49 Background: Impaired mineral ion metabolism is a hallmark of chronic kidney disease (CKD)
50 -metabolic bone disorder. It can lead to pathological vascular calcification (VC) and is
51 associated with an increased risk of cardiovascular mortality. Loss of calcium sensing receptor
52 (CaSR) expression in vascular smooth muscle cells (VSMCs) exacerbates VC *in vitro*;
53 conversely, VC can be reduced by CaSR allosteric activators, calcimimetics.

54 **Methods:** To determine the role of the CaSR in VC, we characterized mice with targeted *Casr* 55 gene knockout (KO) in VSMC (SM22a CaSR $^{\Delta flox/\Delta flox}$).

Results: VSMC cultured from KO mice calcified more readily than those from control (WT) mice in *vitro*. However, KO mice did not show ectopic calcifications *in vivo* but a profound mineral ion imbalance. Specifically, KO mice exhibited hypercalcemia, hypercalciuria, hyperphosphaturia, and osteopenia, with elevated circulating FGF23, calcitriol (1,25-D₃), and PTH levels. Renal tubular, but not vascular α -Klotho protein expression was increased in KO mice. The observed phenotype of the KO mice could not be accounted for by altered CaSR expression in the kidney or the parathyroid glands.

63 Conclusions: These results suggest that the VSMC-CaSR directly contributes to total body
64 mineral ion homeostasis, in addition to the established role of the receptor in the parathyroid65 kidney-bone axis.

66 Introduction

Vascular calcification (VC) is a major complication in chronic kidney disease-metabolic bone 67 68 disorder (CKD-MBD) and is an independent predictor of cardiovascular morbidity and 69 mortality¹. During VC, pro-contractile vascular smooth muscle cells (VSMC) undergo 70 osteogenic transdifferentiation². This process is exacerbated by altered mineral ion homeostasis in CKD-MBD patients^{3, 4}. The CaSR is the key regulator of serum ionized calcium levels, via 71 modulation of parathyroid hormone (PTH) secretion by the parathyroid glands (PTG) as well 72 as Ca²⁺ reabsorption in the kidney⁵. Allosteric CaSR activators, calcimimetics, reduce plasma 73 PTH and Ca²⁺ levels, decrease the prevalence of VC in animal studies of CKD^{6, 7} and reduce 74 75 cardiovascular events in older patients with moderate to severe hyperparathyroidism receiving hemodialysis⁸. However, the CaSR is also expressed in blood vessels where it may have a direct 76 77 protective role against VC. We and others have shown that in VSMC, the CaSR is 78 vasculoprotective, and that there is an inverse relationship between CaSR expression and VC^{9} , ¹⁰. In uremic rats, administration of calcimimetics protects against VC⁹⁻¹⁴. CaSR expression is 79 lost in cultured VSMC kept under pro-calcifying conditions in vitro and in calcified human 80 arteries^{9, 15} an effect which is, at least in part, restored by calcimimetic treatment^{10, 12}. Over-81 82 expression of a "dominant negative" CaSR mutation accelerates calcification of isolated VSMC, which is prevented by calcimimetics⁹. However, there is a discrepancy between the 83 84 preclinical in vitro observations and clinical findings about the role of the CaSR in VC. For 85 instance, CaSR polymorphisms are not determinant of VC or cardiovascular outcomes in renal transplant patients¹⁶, suggesting that the protective cardiovascular effects of calcimimetics in 86 87 advanced CKD-MBD patients may also be modulated by additional systemic or local factor 88 like PTH, vitamin D, and FGF23. Thus, the precise contribution of the vascular CaSR to 89 pathological VC in vivo remains to be fully elucidated. To address this question directly, we 90 studied mice with targeted Casr gene ablation in VSMC, in which we have previously 91 demonstrated a significant role of the receptor in the regulation of blood pressure and vascular
92 tone¹⁷.

93 Materials and Methods

94

95 **Experimental animals**

96 All animal procedures were approved by local ethical review and conformed with the 97 regulations of the UK Home Office and/or the Animal Care and Use Committees of all the 98 participating institutions. VSMC-specific CaSR knock-out mice were produced by breeding CaSR^{flox/flox} mice, which carry 2 loxP sequences flanking exon 7 of the Casr gene¹⁸, with 99 100 SM22α (transgelin)-Cre mice. SM22α is transiently expressed during embryonic development in cardiac myocytes and, by mid-gestation, is confined to visceral and vascular SMCs¹⁹. 101 Genotyping, husbandry, etc. are described in^{17, 20}. SM22aCaSR^{Δflox/Δflox} mice (VSMC-CaSR 102 103 knock-out, **KO**) and Cre-negative, CaSR^{flox/flox} littermates (called "wild-type", for the wild-type 104 CaSR; WT) were used for all experiments. Male mice only were used for all experiments, 105 except for osmolality, soluble CaSR and bone metabolism marker measurements. All mice were 106 on the same C57Bl/6 genetic background.

107 Culture media

108 Dulbecco's modified Eagle medium (DMEM) without CaCl₂, containing 1 mM phosphate, 109 (Life Technologies, Grand Island, NY, USA) was supplemented with 1.2 mM CaCl₂, 50 U/ml 110 penicillin-streptomycin, 2 mM L-glutamine, 10 % (v/v) fetal bovine serum (FBS), 1 mM Na-111 pyruvate and 1 % (v/v) amphotericin B solution (all Life Technologies) was used for the initial 112 isolation of VSMCs (growth medium). For further culturing, the same medium was used but 113 with omission of amphotericin B (culture medium). When indicated, the medium was supplemented with different concentrations of Ca^{2+} and inorganic phosphate (Pi) via addition 114 115 of sterile 1M CaCl₂ solution and inorganic 1M phosphate buffer (NaH₂PO₄ / Na₂HPO₄) pH 7.4.

116 **Primary VSMC isolation**

VSMC were prepared according to published procedure²¹ with modifications. In brief, mice 117 118 were killed by cervical dislocation and the thoracic aorta was dissected. Aortas of 2-5 mice of 119 the same genotype were pooled for one cell isolation and placed in growth medium and cleaned 120 from the tunica adventitia and connective tissue. Segments of aorta ca. 1 mm in length were 121 transferred to a culture flask and, after 10 minutes of drying / attaching in a tissue culture 122 incubator, covered with growth medium and incubated at 37 $^{\circ}$ C / 95 % relative humidity / 5 % 123 CO₂ until cells had grown out of the explants (ca. 2-4 weeks). The explants were then removed 124 by aspiration and the cells were passaged using 0.05 % (v/v) trypsin-ethylenediaminetetraacetic 125 (EDTA) solution in sterile phosphate-buffered saline, pH 7.4 (PBS) without CaCl₂ and MgCl₂ 126 (all Life Technologies). Beginning with this passage VSMC culture medium was used instead 127 of growth medium. Medium was changed every 3-4 days. Cells were used for experiments at 128 passages 2-6. See Figure S1 for a photograph array of the procedure.

129 Immunohistochemistry

130 Mouse organs were fixed by immersion in 4 % (w/v) paraformaldehyde (PFA) in PBS for 4 131 hours and 4 µm paraffin sections were cut and rehydrated according to standard protocols. 132 Immunostainings were carried out to detect CaSR (1:500, MA1-934, Thermo Scientific, 133 Loughborough, UK), TRPV5 (1:400, Alomone Labs, Jerusalem, Israel), Calbindin D-28k 134 (1:3000, Sigma-Aldrich, Gillingham, UK), and PMCA 1/4 (1:100, Santa Cruz Biotechnology, 135 Santa Cruz, USA). These immunostainings were carried out using a Ventana XT autostainer 136 and OmnimapTM DAB reagents (Ventana, Tucson, USA). Hematoxylin (Clin-Tech, 137 Guildford, UK) was used to counterstain the tissue sections, which were then dehydrated in 138 ethanol, cleared in xylene, and mounted using Hystomount (TAAB Labs, Aldermaston, UK) or 139 Fluoromount G (Thermo Fisher). Cyp27b1 and α-Klotho protein in aortas was detected using 140 rabbit anti-Cyp27b1 (1:500, LSBio, Seattle, USA) and rabbit anti-klotho (1:200, Abcam)

141 antibodies, respectively. Antigen retrieval was performed by incubation for 20 min in 10 mM 142 citrate buffer pH 6 in a steamer. Bound antibodies were visualized using the Dako Envision+ 143 HRP rabbit kit (Agilent, Santa Clara, USA), nuclei were counterstained using Haematoxylin 144 and mounted in Fluoromunt G. Tissue slides were scanned using a Scanscope® scanner (Aperio 145 Technologies Incorporated, Vista, USA) or TissueFAXS Hard- and Software (TissueGnostics 146 GmbH, Vienna, Austria). Quantitative evaluation of immunohistochemichal stainings was performed using ImageJ^{22, 23}, where % positive cells / positive area was counted after manual 147 148 thresholding. For the aorta sections, mean color value for endothelium and smooth muscle layer 149 were measured by subtracting the values of the negative controls for each aorta (IgG control) 150 from the positively stained sections.

151 Immunofluorescence

152 Dissected organs were fixed by immersion in 4 % (w/v) PFA in PBS for 4 hours and then 153 washed in PBS and stored in 30 % (w/v) sucrose in PBS at 4 °C for cryosections or dehydrated 154 and paraffin embedded for paraffin sections. For cryosections, tissues were embedded in 155 optimal cutting temperature compound (TissueTek OCT, Sakura-Finetek, Alphen aan den Rijn, 156 NL) on dry ice and 8-10 µm sections were prepared using a cryo-microtome (Leica 2300L, 157 Leica microsystems, Milton Keynes, UK). Rehydrated sections were incubated for 10 minutes 158 in 50 mM NH₄Cl in PBS and then were antigen retrieved in 10 mM citrate buffer pH 6 for 15 159 minutes in a steamer followed by 5 minutes in 1 % sodium dodecyl sulphate (SDS) in PBS. 160 Non-specific antibody binding was prevented by incubation in 1 % (w/v) BSA + 0.1 % (v/v) 161 Tween 20 in PBS (blocking buffer) for 1 hour at room temperature. The CaSR was labelled by 162 incubating the sections overnight with a rabbit-derived polyclonal antibody (1:100; AnaSpec, 163 53286, Fremont, CA, USA) or a mouse derived monoclonal antibody (1:500, clone 5C10, 164 Abcam) in blocking buffer. Negative controls were performed by omission of the primary 165 antibodies or replacement with an isotype control of rabbit IgG (Abcam). After washing in PBS, primary antibody binding was visualized using appropriate Alexa Fluor fluorescence-dye coupled secondary anti IgG antibodies in a dilution of 1:500 in blocking buffer. High background was quenched by incubation of the sections in 0.2 mM Sudan Black B in 70 % ethanol for 10 minutes after the secondary antibody²⁴. Nuclei were counterstained with Hoechst 34580 and slides were mounted using ProLong Gold® (all Life Technologies).

171 In vitro calcification assays

172 Cells were seeded in 24-well plates and were grown to 100 % confluency. The medium was 173 then changed to growth medium supplemented with various CaCl₂ concentrations as specified 174 in the results section. For induction of calcification, Pi (in the form of 1 M Na-phosphate buffer 175 pH 7.4) were added to the culture medium. Cells were left in culture for 10 days and then fixed 176 for 15 minutes in 4 % (w/v) PFA at room temperature. The amount of calcification was visualized by staining with 2 % alizarin red S (w/v) in water, pH 4.3, as described²⁵. For 177 178 quantification, after the incubation period, the cells were washed twice in PBS for and deposited calcium was extracted by decalcifying overnight in 0.6 N HCl at 37 °C. Eluted Ca²⁺ 179 180 concentration was measured using the o-cresolphthalein complexone method^{26, 27} and 181 normalized against total protein concentration of the lysed cells (Pierce BCA assay; Thermo 182 Fisher Scientific).

183 Ex vivo calcification of aortic explants

The assay was performed as described elsewhere²⁸. In brief, aortas were dissected as described for the primary VSMC isolation. After cleaning the aortas from tunica adventitia, the endothelial layer was destroyed by stretching the tissue over the whole length. The vessel was then cut into 3-4 pieces of approximately equal length (5–8 mm). The pieces were incubated for 5 days in growth medium supplemented with varying of CaCl₂ concentrations (1.2–2.5 mM) and 3 mM inorganic phosphate, similarly to the VSMC calcification assays. Ca²⁺ concentrations were measured by o-cresolphthalein complexone method as described above and normalized against the weight of the explants. Typical explant weights varied between 1.0 and 5.0 mg.
Cryosections of 4 % (w/v) PFA fixed WT and KO aortas were stained for calcifications using
Alizarin Red S as described above.

194 Parathyroid isolation and *ex vivo* PTH secretion

The ex vivo PTH-secretion assay in cultured mouse PTGs was adapted from²⁹. Briefly, two 195 196 mouse PTGs cleaned from surrounding tissues were submerged in a micro-droplet (10 µl) of 197 secretion medium [SM, MEM Eagles with Earle's balanced salts supplemented with 0.5 mM 198 Mg, 0.2 % bovine serum albumin, and 20 mM HEPES (pH 7.4)] and placed in the center of a 199 13 mm track-etched (0.1 µM pore) polycarbonate (PC) membrane, floating on a large drop (0.5 200 ml) of ice-cold SM supplemented with 3.0 mM Ca²⁺. When all glands for the same experiment 201 were dissected out, the PC membranes carrying the glands were transferred onto fresh drops of 37 °C SM containing 0.5 mM Ca²⁺ and equilibrated for ~45 minutes. Afterwards, the membrane 202 203 with each pair of glands was transferred sequentially to a fresh drop (500 µl) of SM at 37 °C. increasing the Ca²⁺ concentration in the medium from 0.5 to 3.0 mM with 60 min for each 204 205 concentration and a fresh medium change midway (at 30 minutes). Intact PTH released into the 206 culture media was determined by ELISA (Quidel, San Diego, USA) in duplicate and used to calculate the rate of PTH release. For Ca²⁺ set-points, rates of PTH release were normalized to 207 the rate at 0.5 mM Ca^{2+} and plotted against the Ca^{2+} concentration, and the PTH set-points (= 208 EC₅₀) were deduced from the curve as the Ca²⁺ concentration which inhibits 50 % of the Ca²⁺-209 210 suppressible PTH release.

211 Microcomputed tomography (µCT)

 μ CT was performed on distal femur for trabecular (Tb) bone and tibio-fibular junction (TFJ) for cortical (Ct) bone as described²⁹. Briefly, femurs and tibiae fixed in 10 % phosphatebuffered formaldehyde (PBF) were scanned by a SCANCO vivaCT 100 scanner (SCANCO Medical AG, Basserdorf, Switzerland) with 10.5 µm voxel size and 55 kV X-ray energy. For 216 Tb bone in the distal femoral metaphysis, 100 serial cross-sectional scans (1.05 mm) of the 217 secondary spongiosa were obtained from the end of the growth plate extending proximally. For Ct bone, 100 serial cross-sections (1.05 mm) of the tibia were obtained from the TFJ extending 218 proximally. A threshold of 420 mg hydroxyapatite (HA)/mm³ was applied to segment total 219 220 mineralized bone matrix from soft tissue. Linear attenuation was calibrated using a µCT HA 221 phantom. μ CT image analysis and 3D reconstructions were done using the manufacturer's 222 software to obtain the following structural parameters: Tb tissue volume (Tb.TV), Tb bone 223 volume (Tb.BV), Tb.BV/TV ratio, Tb number (Tb.N), Tb connectivity density (Tb.CD), Tb 224 thickness (Tb.Th), Tb spacing (Tb.Sp), Ct tissue volume (Ct.TV), and Ct thickness (Ct.Th).

225 Nephron count

One kidney per adult animal (16 weeks) was removed, decapsulated and immersed in 6M HCl at 37°C for 35 minutes. After several washes with tap water, the macerated kidney was stored at 4°C overnight. The tissue was homogenized with a glass-stirring rod and transferred to a 50 ml volumetric flask. Tap water was added to adjust the volume and the tubules and glomeruli suspension was then ready for nephron counting. One 0.5 ml aliquot was taken and deposited onto a glass slide with a millimeter mesh lattice to count the number of glomeruli. The total number of nephrons per kidney was calculated using the mean of 3 to 4 counts.

233 Tissue preparation for Western blot and RT-qPCR experiments

Mouse kidney slices were prepared as previously described³⁰. In brief, WT and KO mice were euthanized by cervical dislocation. Kidneys were quickly removed and about 500 µm sections were made. Sectioned kidneys were equilibrated for 10 min in a specific kidney-slice buffer that contained 118 mM NaCl, 16 mM HEPES, 17 mM Na-HEPES, 14 mM glucose, 3.2 mM KCl, 2.5 mM CaCl₂, 1.8 mM MgSO₄, and 1.8 mM KH₂PO4 (pH 7.4) at 37°C. For Western blotting experiments, sections were then homogenized with a mini-potter in ice-cold kidney-slice slice buffer and HaltTM protease and phosphatase inhibitor Cocktail (Thermo Fisher, Rockford,

USA). Suspensions were centrifuged at 12,000 x g for 10 min at 4°C, and supernatants were loaded on acrylamide gels. Bones were prepared from hind-leg bones (femur, tibia and fibia) after cleaning of the surrounding connective tissue. After cleaning of the aortas from the tunica adventitia, the vessel was cut into 3-4 pieces, which were then processed accordingly.

For RT-PCR experiments, total RNA was extracted from kidneys, aorta and bones using Trizol
reagent according to the manufacturer's instructions (Invitrogen, Life Technologies, Monza,
Italy).

248 Gel Electrophoresis and Immunoblotting

Proteins were separated on 8-13 % bis-tris acrylamide gels under reducing conditions. Protein
bands were electrophoretically transferred onto Immobilon-P membranes (Millipore Corporate
Headquarters, Billerica, USA) for Western blot analysis, blocked in TBS-Tween-20 containing
3 % bovine serum albumin (BSA) and incubated with primary antibodies overnight.

253 Antibodies: polyclonal rabbit anti-CaSR (AnaSpec, this antibody had previously been determined to be most suitable for mouse tissue³¹), polyclonal rabbit anti-AQP2 (raised against 254 255 20-amino acids at the N-terminal, custom made from the polyphosphorylated region of rat AQP2)³², polyclonal rabbit anti-AQP2-pS256 (a gift from Peter Deen)³³, polyclonal rabbit anti-256 257 AQP2-pS261 (Novus Biologicals, Littleton, Colorado, USA), polyclonal antibody against 258 NaPi2a (Alpha Diagnostic Intl. Inc, San Antonio, Texas, USA), polyclonal rabbit anti-Klotho 259 (Abcam, Cambridge, UK), monoclonal mouse anti-NCC (StressMarg Biosciences Inc., 260 Victoria, CDN), polyclonal rabbit anti- β -actin (Cell Signaling Technology, Leiden, NL) and 261 rabbit antibodies raised against the last 10 C-terminal amino acids (C-GANANRKFLD) of the 262 E subunit of the V-ATPase (a gift from Dr Dennis Brown, Harvard Medical School, Boston, 263 MA, USA). Secondary goat anti-rabbit or goat anti-mouse horseradish peroxidase-coupled 264 antibodies were obtained from Santa Cruz Biotechnologies (Tebu-Bio, Milan, IT). Membranes 265 were developed using Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford,

USA) with Chemidoc System (Bio-Rad Laboratories, Milan, Italy). Densitometry analysis was
performed using Image Lab from Bio-Rad Laboratories, Inc. (Hercules, California, USA).

268 **Real-Time PCR**

269 Real-Time PCR experiments were performed to measure the relative expression of mRNA from 270 WT and KO mouse kidneys, aorta, and bone. Total RNA was extracted using Trizol (Invitrogen, 271 Life Technologies, Monza, Italy). Reverse transcription was performed on 1 µg of total RNA 272 using SuperScript VILO Master Mix (Invitrogen, Life Technologies, Monza, Italy). Real-time 273 PCR amplification was performed using TaqMan® Fast Advanced Master Mix with Aqp2 (ID 274 number: Mm00437575_m1), CaSR (ID number: Mm00443375_m1), α-Klotho (ID number: Mm00502002_m1), NaPi2a (ID number: Mm00441450 m1), Tagln or Sm22a (ID number: 275 276 Mm00441661 g1), FGF23 (ID number: Mm00445621 m1) and CYP27B1 or 1α-hydroxylase 277 (ID number: Mm01165918_g1) assay, using GAPDH (ID number: Mm99999915_g1) and 18S 278 (ID number: Hs99999901_s1) assay as housekeeping genes (Applied Biosystem, Life 279 Technologies, Monza, Italy) in a StepOne Real-Time PCR System (Applied Biosystem, Life 280 Technologies, Monza, Italy). Results were calculated according to the $\Delta\Delta$ Ct method as relative 281 expression to the average gene expression in the WT samples and then calculated as fold changes via $2^{-\Delta\Delta Ct}$. 282

Blood and urine collection, metabolic cages

Post-mortem blood collection from animals after neck dislocation was performed *via* cardiac puncture or retro-orbitally. Blood collection from live animals was performed *via* tail nick, as described ³⁴. K-EDTA, Na-heparin plasma and serum were collected in respective tubes (BD Biosciences, Oxford, UK). The blood was then centrifuged at 2,000 x *g* for 10 minutes and the supernatant stored at -80 °C. For urine collection, mice were weighed and transferred to metabolic cages (Tecniplast, Buguggiate, IT) and then left for 48 hours to allow them to acclimatize to the new environment. Mouse weight, food and water intake, as well as feces and urine production were recorded over a period of 4 days. Samples from day 3 and 4 were then
used for urine analysis and the results for both days were averaged. Urine was stored at -80 °C
for further analysis.

294 Blood and urine analysis

295 Commercially available assays were used to measure plasma concentrations of Fetuin A (R&D 296 Systems, Abingdon, UK), pyrophosphate (Abcam), FGF 23 (Kainos Laboratories, Tokyo, 297 Japan), 1–84 PTH (Immutopics, San Clemente, USA), calcitriol (1,25-D₃) (Immunodiagnostic 298 Systems, Tyne & Wear, UK), P1NP (Immunodiagnostic Systems), and TRAcP5b 299 (Immunodiagnostic Systems), as well as serum concentration of soluble CaSR / N-terminal 300 CaSR fragment (Elabscience, Wuhan, CN), and α-Klotho (cloud Clone Corp., Wuhan, CN). 301 Concentrations of electrolytes were analyzed using a Roche modular P analyzer (Roche 302 diagnostics) or, as were urea, creatinine, uric acid, glucose, and protein, by a commercially 303 available clinical pathology service (MRC Harwell, Oxford, UK). Serum osmolality was 304 measured using an Osmomat 30 (Gonotec, Berlin, DE) freezing point depression osmometer. 305 Electrolyte concentrations for urine are reported as ion:creatinine ratio (abbreviated as ion:Cr), 306 other clinical urine biomarkers (creatinine, total protein, urea and uric acid) are reported as 307 excreted amount per day and total body weight (TBW). Urine osmolality was measured using 308 a VAPRO® vapor pressure osmometer 5520 Wescor Inc., (Puteaux, France). Urine pH was 309 measured using litmus paper with a range of pH between 2.0 and 9.0 (Macherey-Nagel, Düren, 310 Germany). For urine precipitated analysis, 20 µl of urine were placed on the glass slide and 311 covered with a coverslip. Samples were studies with phase contrast microscopy and analyzed qualitatively. Urinary AQP2 excretion was measured by ELISA as previously described^{35, 36}. 312

313 Statistical Analysis

All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, La Jolla,
CA, USA). Statistical sample size is reported as N (number of separate experiments / biological

repeats) over n (technical repeats per sample, where applicable). Data are generally presented as mean \pm SD, except for RT-qPCR data, which are shown as median \pm interquartile range. A difference of *p*<0.05 was considered statistically significant. The employed statistical tests and significance levels are specified in the respective results sections or in the figure legends.

320 **Results**

321 CaSR ablation induces calcification of VSMC *in vitro* but not *ex vivo* or *in vivo*.

Effectiveness of CaSR ablation from VSMC of SM22aCaSR $\Delta flox/\Delta flox$ mice, at the molecular and 322 functional levels, had already been confirmed previously^{17, 37}. To test directly whether CaSR 323 324 ablation prompts VSMCs to calcify, VSMC isolated from WT and KO mice were cultured in rising concentrations of Ca²⁺ (0.8–2.2 mM) and inorganic phosphate (Pi, 2–3 mM), spanning 325 the (patho)physiological range. WT VSMC showed no calcification at 2 mM Pi at any Ca²⁺ 326 concentration, while at 3 mM Pi, calcification was seen at >1.6 mM Ca²⁺. In VSMC derived 327 from KO aortae, calcification was significantly greater, and was already observed in 2 mM Pi 328 at 1.6 mM Ca²⁺ or in 3 mM Pi at 1.2 mM Ca²⁺ (Figure 1A). Ca²⁺ incorporation in VSMC was 329 Ca²⁺-concentration dependent and was markedly more pronounced in VSMC from KO than in 330 331 those from WT mice (Figure 1B). Furthermore, VSMC from WT and KO mice were cultured in 3 mM Pi and only 1.2 mM Ca²⁺, so as to not saturate CaSR-activation, but in combination 332 333 with 10 nM of the calcimimetic R-568. R-568 reduced calcium incorporation only in WT but 334 not KO VSMC when compared to vehicle control (Figure 1C). Together, these results 335 confirmed that the CaSR protects in vitro VSMC calcification.

Based on these observations, we had expected the KO mice to develop calcification in their blood vessels. However, there was no evidence of increased *in vivo* Ca^{2+} incorporation in the aortas of three-month-old KO mice compared to age matched WT controls. *Ex vivo* whole aortic explants from both six-month-old KO and WT mice, kept for ten days in 3 mM Pi and 1.8 mM 340 Ca^{2+} did not show any traceable calcification by alizarine red staining (**Figure S2**) and/or μ CT 341 (data not shown). Finally, as shown previously, aortas from up to 12-month-old WT and KO 342 mice were histologically comparable and devoid of calcium deposits¹⁷.

343

344 SM22αCaSR^{Δflox/Δflox} mice exhibit impaired mineral ion homeostasis and alterations 345 in calciotropic and phosphotropic hormones.

346 Blood biochemistry

Measurement of blood parameters, as shown in **Table 1**, showed moderate hypercalcemia and elevated plasma FGF23, PTH and 1,25-D₃ levels in 3-month-old mice. FGF23 and Ca²⁺ levels were also measured and found to be elevated in 18-month-old mice (**Table S1**) indicting that the mineral ion imbalance persists throughout the lifespan of the KO mice, without any apparent detrimental impact on their health. Serum α -Klotho-levels were comparable between both genotypes, at 3- and 18-months of age, although older mice had higher mean α -Klotho-levels than the younger ones.

354 Plasma Pi concentrations were reduced in 3-month-old KO compared to WT animals while Na⁺, K⁺, Cl⁻ and Mg²⁺ levels, and the levels of the physiological inhibitors of calcification, 355 356 inorganic pyrophosphate (PPi) and Fetuin A were comparable between genotypes. Serum 357 albumin levels were slightly decreased (pointing also towards a higher proportion of free ionized Ca²⁺ levels) while alkaline phosphatase (ALP) levels were increased in KO animals. 358 359 Kidney function and hydration appeared to be normal in KO mice as urea and blood urea 360 nitrogen (BUN), as well as hematocrit, did not differ from those of WT animals, while serum 361 creatinine was slightly reduced in KO animals (**Table 1**). Serum osmolality assessed in the 18-362 month-old animals was unchanged between the two genotypes (Table S1). We also detected 363 no difference in the concentration of "soluble" CaSR or rather N-terminal CaSR fragment 364 between the genotypes in sera of 18-month-old animals (Table S1) which was comparable to the level seen in serum of a 14-month-old non-genetically modified control (Ctrl) mouse.
"Soluble" CaSR was around the lowest detection limit in sera of 3-month-old animals (Figure
S8). These results exclude an antagonistic or hormonal effect of the truncated CaSR (encoded
by exons 2-6) as the cause for the observed phenotype.

369

370 Metabolism, urine and organ weight

Urinary Ca²⁺:Cr and Pi:Cr levels of KO were strongly elevated compared to WT animals (7.2fold and 2.9-fold respectively), while Na⁺:Cr, K⁺:Cr, Cl⁻:Cr and Mg²⁺:Cr, creatinine, total
protein, urea, uric acid, and glucose excretion ratios were comparable between the genotypes
(Table 2). No differences in food consumption or fecal output were observed between
genotypes. Water consumption and urine excretion were non-significantly elevated in KO mice
compared to WT (Table 2, Figure S3).

377

378 Mineral ion and hormonal imbalance seen in $SM22aCaSR^{flox/\Delta flox}$ mice is not a direct 379 consequence of altered gene/protein expression in the vasculature (aorta).

The observed phenotype points to a profound mineral ion dyshomeostasis in KO mice. We therefore investigated the expression of α -Klotho and 1α -hydroxylase since they are powerful regulators of mineral ion metabolism. mRNA expression of α -*Klotho*, *Cyp27b1*, and the smooth muscle marker *sm22* α were unchanged between WT and KO animals. CYP27B1 and α -Klotho protein expression levels were comparable between genotypes in both the endothelium and smooth muscle layers of the aorta (**Figure 2**). The cause of the observed mineral ion and hormonal imbalance in KO mice must therefore lie elsewhere.

388 $SM22\alpha CaSR^{\Delta flox/\Delta flox}$ mice exhibit altered expression of renal α -Klotho and of Ca^{2+} and Pi 389 transport proteins.

390 Renal expression of α -Klotho protein was significantly increased while that of the proximal 391 tubule Na⁺-dependent Pi transporter NaPi2a was significantly decreased in the kidneys of KO 392 mice. The number of vitamin D receptor positive cells over whole kidney sections as 393 determined by semi-quantitative immunohistochemistry analysis was comparable between 394 genotypes, as was the mRNA expression of *Cyp27b1* (Figure 3 and Figure S4). The elevated 395 plasma levels of 1,25-D₃ seen in KO mice could not be explained by the unchanged CYP27B1 396 protein expression in the kidney, which was comparable between genotypes (Figure S5), 397 indicating extrarenal sources of 1,25-D₃. In supporting the action of 1,25-D₃ to increase urinary Ca^{2+} reabsorption³⁸, the expression of the epithelial Ca^{2+} channel TRPV5, the cytosolic Ca^{2+} 398 buffer calbindin D28K, and the basolateral plasma membrane Ca2+-ATPase (PMCA) was 399 400 significantly increased in kidneys from KO compared to WT mice, as indicated by the larger 401 area where staining intensities were above the threshold level (Figure 3).

402 Next, we confirmed that CaSR ablation from VSMC did not yield altered CaSR expression or 403 gross anatomical changes in the kidney which could account for the observed phenotype. Renal 404 CaSR mRNA and protein expression and distribution pattern (**Figure 3**, **Figure S6**) were all 405 comparable between genotypes. There were no histomorphological differences between the 406 kidneys of WT and KO mice of comparable age (**Figure S6A**, **B**). Kidney weights were 407 comparable between WT and KO animals, both at 6 and 18 months of age (**Table S2**), as were 408 nephron numbers (WT 30.54±5.21 *vs* KO 31.63±4.80 nephrons/mg kidney, mean±SD, N=7).

410 hearts of 18-month-old KO animals, which were slightly heavier than those of age-matched WT

Other organ weights (liver, stomach, spleen) were similar between genotypes, except for the

411 animals (**Table S2**).

412

413 Urinary crystals, dilution and aquaporin expression levels of $SM22\alpha CaSR^{\Delta flox/\Delta flox}$ mice.

414 The observed hypercalciuria and hyperphosphaturia could promote renal stone formation. 415 While overt nephrolithiasis or nephrocalcinosis were not detected by histopathology, we did 416 observe micro crystals in the urine of KO, but not WT animals (Figure 4A). Urine of KO mice 417 had significantly reduced osmolality and pH compared to WT controls (Figure 4). The 418 expression of the apical thiazide-sensitive Na⁺-Cl⁻ cotransporter (NCC) and of the V-type H⁺ 419 ATPase were significantly increased in KO mouse kidneys, potentially leading to increased 420 NaCl reabsorption and urine acidification respectively. Accordingly, the expression of the 421 aquaporin-2 water channel (total AQP2) was significantly reduced in the kidneys of KO mice 422 at both the mRNA and protein levels (Figure S4 and Figure 4F). Specifically, the expression of the proteasome-sensitive phosphorylated form of AQP2, pS261³⁹, was upregulated while the 423 active, vasopressin-stimulated pS256-AQP2³⁵ was downregulated in KO mice (Figure 4G, H), 424 425 indicating a decreased amount of functional AQP2 resulting in decreased renal concentrating 426 ability. In addition, urinary excretion of AQP2 was increased in KO animals (Figure 4I), 427 pointing towards a higher degree of AQP2 degradation. Overall, KO mice had reduced urine 428 concentrating ability, possibly as compensation to prevent kidney stone formation.

429

430 Hyperparathyroidism of SM22aCaSR $\Delta flox/\Delta flox$ mice is neither due to altered CaSR expression, 431 nor function, in the PTG.

432 VSMC-CaSR KO mice exhibit hypercalcemia and mild hyperparathyroidism (to reiterate, 433 plasma total Ca²⁺: 2.28 mmol / 1 *vs*. 2.94 mmol / 1 and PTH 151.7 *vs*. 256.6 pg/ml, WT *vs*. KO, 434 see **Table 1**).To investigate whether the observed phenotype was due to partial ablation of the 435 parathyroid CaSR, possibly through *SM22a* promoter leakage, we characterized CaSR 436 expression and PTG function in the KO animals. PTGs from WT and KO animals were 437 comparable in size and morphology (**Figure 5A**), as was the glands' CaSR expression (**Figure** 438 **5B and C**). Similarly, isolated PTGs had overlapping PTH secretion curves in response to rising 439 levels of extracellular Ca²⁺ for both genotypes with identical IC₅₀ values of ~ 1.1 mM Ca²⁺_o 440 (**Figure 5D**). Thus, the profound changes in mineral ion homeostasis seen in KO animals cannot 441 be accounted for by altered CaSR expression, or function, in the PTGs.

442

443 $SM22aCaSR^{\Delta flox/\Delta flox}$ mice exhibit elevated bone FGF23 levels and osteopenia.

The increased circulating levels of the phosphaturic hormone FGF23 are, at least in part, of
skeletal origin, as FGF23 mRNA expression levels were increased in bones of KO mice (Figure
S7). In contrast, FGF23 mRNA was undetectable in blood vessels of both genotypes (no
amplification).

448 Micro-computerized tomography (μ CT) on hind-leg bones of 3-month-old WT and KO mice 449 revealed that especially trabecular bone quality was significantly reduced in KO animals 450 compared to WT (**Table 3, Figure S7**). These findings are in line with a significant increase in 451 plasma levels of the bone resorption marker tartrate-resistant acid phosphatase 5b (TRAcP5b) 452 in KO compared to WT animals, while the bone formation marker procollagen type 1 (P1NP) 453 was comparable in both genotypes (**Figure S7**).

454 **Discussion**

Our data suggest that the CaSR protects VSMC from calcification *in vitro*, though loss of the VSMC-CaSR is apparently unable to induce detectable VC *in vivo*. Our mouse model further demonstrated that the VSMC-CaSR contributes directly to the regulation of mineral ion homeostasis, possibly by direct control of FGF23 and 1,25-D3 production / secretion, or indirectly through influencing the calcium-sensing or hormonal resistance in calciotropic organs. Most likely, the phenotype of the ^{SM22a}CaSR^{Δ flox/ Δ flox</sub> mouse is the result of a combination of disturbances acting together (**Figure 6**).}

462 Vascular and VSMC calcification

463 VC is an independent predictor of cardiovascular morbidity and mortality in CKD-MBD patients^{40, 41}. Previous observations in cultured human and bovine VSMC⁹ indicated a direct 464 role for the CaSR in preventing VSMC calcification / VC, which is substantiated by our findings 465 466 on the effect and ability of CaSR ablation and calcimimetics to enhance and prevent VSMC 467 calcification in vitro, respectively. These observations suggest that calcimimetics used 468 clinically to treat patients with end-stage renal disease may reduce VC by directly targeting the 469 vascular CaSR in addition to its action of improving mineral ion metabolism. However, the 470 absence of VC in the aortae of KO mice in vivo, despite the animals' hypercalcemia, suggests 471 that loss of CaSR expression is not sufficient to drive pathological VC.

472 An increase in 1α -hydroxylase expression in the vasculature promotes VC⁴² but 1α -hydroxylase 473 expression in the aortas of $SM22aCaSR^{\Delta flox/\Delta flox}$ mice is not affected. High serum Pi levels are 474 associated with greater prevalence of VC in patients with moderate CKD⁴³ whereas the 475 $SM22aCaSR^{\Delta flox/\Delta flox}$ were hypophosphatemic. Together with unchanged fetuin A and 476 pyrophosphate (PPi) levels, potentially in combination with factors such as reduced vascular 477 resistance in these animals¹⁷, this may explain the lack of *in vivo* VC of $SM22aCaSR^{\Delta flox/\Delta flox}$ mice.

478 Mineral ion metabolism imbalance

In addition to the previously described phenotype of reduced vascular contractility¹⁷ and the changes in VSMC calcification behavior discussed above, we found that the ${}^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mice also showed dysregulated mineral ion imbalance, manifesting in hypercalcemia, hypophosphatemia, hypercalciuria, hyperphosphaturia, and elevated FGF23, PTH, and 1,25-D₃ levels, together with increased bone resorption that is probably due to the chronically elevated PTH levels.

485 The phenotype is a direct consequence of VSMC-specific CaSR deletion

CaSR expression and / or function in PTG and kidney was not affected in the $SM22aCaSR^{\Delta flox/\Delta flox}$ 486 487 mice. Indeed, the phenotype of these mice cannot be explained by off-target CaSR deletion 488 induced by our knock-out strategy, as constitutive or calciotropic organ specific CaSR deletion 489 have very different phenotypes (Table 4). The global CaSR knock-out mouse exhibits severe hyperparathyroidism, growth retardation, and rarely lives longer than a few weeks⁴⁴ while the 490 $^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mice grow normally and have a normal lifespan. Using our strategy ($\Delta exon$ 491 492 7), targeted deletion of the CaSR from the PTG was shown to induce a severe phenotype of hypercalcemia and hyperparathyroidism (~20-fold higher compared to controls)¹⁸, along with 493 PTGs whose secretion are totally unresponsive to rising Ca²⁺ concentrations⁴⁵. The PTGs of the 494 $SM22aCaSR^{\Delta flox/\Delta flox}$ mice however were as responsive to extracellular Ca²⁺ as those from WT 495 496 mice. A similar strategy ($\Delta exon 3$) was used to specifically delete the CaSR from the kidney, 497 and these mice exhibit normal serum biochemistries and hypocalciuria⁴⁶. Off-target effects of 498 the truncated amino terminus of the CaSR are also highly unlikely, given that circulating levels 499 of the (truncated) receptor were extremely low which would not be expected to interfere with the millimolar extracellular Ca²⁺ concentration, and that the residual truncated protein is by 500 itself inactive and does not hinder the function of the native CaSR¹⁸. Collectively, these 501 502 considerations suggest that the observed phenotype can only be reasonably accounted for by 503 CaSR ablation from VSMC.

504 Features of the phenotype likely to be secondary to disturbed hormone secretion

505 The hypercalcemia of the ${}^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mouse is most likely downstream to the increase 506 in PTH and particularly 1,25-D₃ levels whereas the observed hypercalciuria is likely secondary 507 to the hypercalcemia. ${}^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mice also showed hyperphosphaturia and 508 hypophosphatemia, likely *via* FGF23 and PTH induced down-regulation of NaPi2a and thus 509 decreased phosphate reabsorption from the urine. The mildly increased PTH levels are also 510 plausibly the cause for reduced bone mineral density together with an increase in the bone 511 resorption in the $SM22aCaSR^{\Delta flox/\Delta flox}$ mice.

512 The underlying regulatory schemes become more complex when looking at the hormones themselves. The increase in 1,25-D₃ production could be secondary to the increase in PTH, 513 514 though the hyperparathyroidism seems quite mild for such an effect. Also, given that the higher 515 serum Pi would be expected to limit CaSR activation⁴⁷ by extracellular Ca²⁺, the hypercalcemia and hypophosphatemia seen in the $SM22aCaSR^{\Delta flox/\Delta flox}$ mice would provide optimal conditions 516 517 for enhanced CaSR activation in the parathyroid and thus reduced PTH secretion, instead of hyperparathyroidism. These observations along with the unaltered Ca²⁺-set point of PTH 518 519 secretion from KO PTGs suggest that loss of CaSR in VSMC influences other mechanisms to 520 promote PTH release in vivo.

521 The increase in 1,25-D₃ and PTH could then contribute to the elevated circulating FGF23 levels 522 which are, at least in part, of skeletal origin given that FGF23 mRNA was undetectable in the 523 aorta but was increased in the bones of $SM22aCaSR^{\Delta flox/\Delta flox}$ mice.

524 *Features of the phenotype likely to be caused by end-organ resistance*

1,25-D₃ is a potent inducer of FGF23⁴⁸ and, conversely, FGF23 reduces the production of 1,25-525 D_3 by downregulating 1 α -hydroxylase^{49, 50} and by upregulating 24-hydroxylase⁴⁹. However, in 526 the SM22aCaSR^{Aflox/Aflox} mice, PTH and 1,25-D₃ levels were increased in KO mice despite the 527 elevated FGF23 levels, indicating resistance of PTH and 1,25-D₃ synthesis to control by FGF23 528 529 and pointing away from FGF23 as sole primary factor. It is possible though that the high 1,25-530 D₃ and FGF23 levels actually mitigate PTH secretion, contributing to the only relatively mild 531 increase in serum PTH in these mice – although there seems to be a degree of resistance to 1,25-D₃ and serum Ca²⁺ there as well. Taken together, given its resistance to control by FGF23, 1,25-532 533 D₃ could be the integrating element leading to the combined and complex phenotype observed 534 in these mice.

However, FGF23 resistance does not seem to be a general feature of the $SM22aCaSR^{\Delta flox/\Delta flox}$ 535 536 mice, as regulation of renal phosphate reabsorption is apparently not affected. A factor that 537 might play a role here is α -Klotho, which is acting both locally as co-factor for FGF23 and 538 systemically in hormonal fashion⁵¹. Indeed, the observed hypercalcemia, elevated 1,25-D₃ and FGF23 levels and osteopenia of the $SM22aCaSR^{\Delta flox/\Delta flox}$ mice are, except for the elevated PTH 539 levels, somewhat reminiscent of the phenotype of the global Klotho^{-/-} mice (**Table 4**). This 540 suggests a common role for the VSMC-CaSR and α -Klotho in Ca²⁺ and Pi homeostasis, as 541 542 already suggested by the biochemical interaction between CaSR and α -Klotho in the PTG⁵² and in the kidney⁵³. The kidney is the major site of α -Klotho production⁵⁴ where changes in serum 543 and urinary α -Klotho mirror those of renal α -Klotho levels⁵⁵. Interestingly, in the 544 $SM22aCaSR^{\Delta flox/\Delta flox}$ mice, even though renal α -Klotho levels were increased, vascular or 545 546 circulating α -Klotho levels were not affected, suggesting that absence of CaSR from VSMC 547 influences circulating and local α -Klotho metabolism differently.

Elevated serum FGF23 may be an independent predictor of cardiovascular mortality⁵⁶. Experimentally, FGF23 alone can directly induce LVH⁵⁷ and FGF23 gain of function leads to volume expansion, hypertension, and cardiac hypertrophy⁵⁸. Despite chronically elevated FGF23 levels, our $^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mice did not develop LVH at 14 months of age and we did not observe increased mortality^{17, 37}. Since these mice are hypotensive despite their chronically elevated FGF23 levels, vascular contractility may play a larger role here than FGF23 mediated renal and cardiac effects on blood pressure.

555 Renal phenotype

556 The expression of TRPV5, calbindin D28K and PMCA were all increased in the kidneys of the 557 $S^{M22a}CaSR^{\Delta flox/\Delta flox}$ mice, suggesting higher transcellular Ca²⁺ reabsorption. This increase, due 558 to chronic elevation of 1,25-D₃, PTH, and FGF23⁵⁸ levels, may contribute to their 559 hypercalcemia, whereas the increased renal NCC expression is likely to contribute to the observed hypercalciuria, as serum and urine Mg^{2+} levels were unaffected in KO mice, suggesting that the abnormality indeed lies within the NCC-expressing distal convoluted tubule⁵⁹, rather than the thick ascending limb, where Ca^{2+} and Mg^{2+} reabsorption happen in parallel driven by the transepithelial potential difference⁶⁰.

The hypercalciuria and hyperphosphaturia of the $^{SM22a}CaSR^{\Delta flox/\Delta flox}$ mice could be the cause for 564 565 the formation of the observed micro crystals in their urine. We did not observe nephrolithiasis 566 in these animals, which can be explained by a CaSR-mediated compensatory mechanism of urine dilution and acidification. In the collecting duct principal cells, the CaSR⁶¹ is co-expressed 567 luminally with AQP2^{39, 62-65}, and decreases water reabsorption by reducing the apical insertion 568 569 of AQP2 water channels. In intercalated cells, the CaSR induces luminal acidification by 570 activating the V-type H⁺ ATPase. In $SM22aCaSR^{\Delta flox/\Delta flox}$ mice, renal AQP2 expression levels 571 were reduced while urinary excretion of degraded AQP2 was increased, indicating decreased 572 water reabsorption, and explaining the reduction of urine osmolality. Furthermore, renal V-573 ATPase expression was increased in $SM22aCaSR^{\Delta flox/\Delta flox}$ mice compared to WT controls, 574 explaining their acidified urine.

575 Implications and conclusions

576 Our study may also have important clinical implications. Physiological pulsation is necessary 577 for the maintenance of CaSR expression in human aortic smooth muscle cells and may protect arteries from developing VC⁶⁶. Thus, in early CKD, an increase in arterial stiffness and blood 578 579 pressure, could potentially yield a reduction in CaSR expression by VSMC. While absence of 580 the CaSR apparently does not prompt immediate VC in the blood vessels in vivo, it could 581 contribute to the disease onset via the deleterious effects of VSMC-CaSR loss on mineral ion 582 homeostasis, as observed in our mouse model. A reduction in blood pressure could thus slow 583 the VSMC-CaSR loss-induced disease progression. Furthermore, a reduction in blood pressure 584 below what is recommended by most guidelines led to improved cardiovascular and all-cause 585 mortality in the CKD population⁶⁷. Our study supports these findings and points to an early 586 targeting of blood pressure control to delay CKD progression. Owing to their ability to affect 587 the VSMC-CaSR, calcimimetics would also be expected to be directly vasculoprotective, in 588 addition to their systemic effects mediated by suppression of circulating PTH and FGF23 levels. 589

590 The VSMC-CaSR apparently contributes to mineral ion homeostasis control, possibly by direct 591 control of FGF23 and 1,25-D₃ production / secretion, though the phenotype of the SM22a CaSR $\Delta flox / \Delta flox$ mouse is likely to be the result of a combination of disturbances acting 592 593 together. Global deletion of the CaSR from VSMC might affect calcium-sensing in all 594 calciotropic organs to some degree, suggesting a role for the VSMC-CaSR in contributing to 595 each individual organ's response to mineral ion homeostasis. Further work will be necessary to 596 dissect the organ-specific paracrine/autocrine responses vs whole body endocrine feedback 597 mechanisms for the fine control of mineral ion homeostasis that the VSMC-CaSR evidently 598 supports.

600 Author contributions

- 601
- 602 DR, WC, and MSch designed the study;
- 603 MSch, MR, ILF, TSW, SCB, PLY, JG, TM, MSa, CLT, CM, HQ, SAP, DTW, TG, VVM, RAF, AH, JH, CSM and
- 604 WC carried out experiments;
- MSch, MR, TSW, CM, RAF, UKH, DTW, VVM, TG, CSM, JH, WC, EK and GV analyzed the data;
- 606 MSch, MR, TSW and WC made the figures;
- 607 MSch, MR, WC, SCB, GV, SAP, VVM, RAF, EK and DR drafted and revised the paper;
- 608 All authors approved the final version of the manuscript.

609 Acknowledgements

- 610 The authors want to acknowledge B. Monk, B. van der Kolk, A. Wheatley, P. Edwards, and N.
- 611 Kupper for their help with some of the initial experiments and revisions, and Professor AE
- 612 Canfield and Dr B. Richards for helpful discussions.

613 **Disclosures**

614 The authors have no disclosures and no competing financial interests.

615 Funding

- 616 EU Marie Curie Innovative Training Network Grant FP7-264663 "Multifaceted CaSR" (to DR,
- 617 SAP and EK), Austrian Science Fund P-29948-B28 (to EK), Austrian Science Fund and
- 618 Herzfelder'sche Familienstiftung P-32840-B (to MSch), "Intervento cofinanziato dal Fondo di
- 619 Sviluppo e Coesione 2007-2013-APQ Ricerca Regione Puglia, Programma Regionale a
- 620 Sostegno della Specializzazione Intelligente e della Sostenibilità Sociale ed Ambientale -
- 621 FutureInResearch." CHVNKZ4 (to MR), Kidney Research UK (Intercalated Scholarship) (to
- 622 UKH), NIH R01DK12165601, R01DK122259, and VA-BLR&D I01BX005851 and
- 623 1IK6BX004835 (to WC).

625 **References**

- London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications
 and cardiovascular disease in uremia. *Curr Opin Nephrol Hypertens*, 14: 525-531, 2005
- Villa-Bellosta R, Millan A, Sorribas V: Role of calcium-phosphate deposition in vascular
 smooth muscle cell calcification. *Am J Physiol Cell Physiol*, 300: C210-220, 2011
 10.1152/ajpcell.00229.2010
- 3. Yamada S, Giachelli CM: Vascular calcification in CKD-MBD: Roles for phosphate, FGF23,
 and Klotho. *Bone*, 100: 87-93, 2017 10.1016/j.bone.2016.11.012
- 4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral
 metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*,
 15: 2208-2218, 2004 10.1097/01.ASN.0000133041.27682.A2
- 636 5. Riccardi D, Valenti G: Localization and function of the renal calcium-sensing receptor. *Nat* 637 *Rev Nephrol*, 12: 414-425, 2016 10.1038/nrneph.2016.59
- 6. Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, et al.: Etelcalcetide, A
 Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal
 Insufficiency with Secondary Hyperparathyroidism. *Calcif Tissue Int*, 101: 641-653,
 2017 10.1007/s00223-017-0319-7
- 642 7. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, et al.: R-568 reduces ectopic
 643 calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD644 MBD). *Nephrol Dial Transplant*, 24: 2371-2377, 2009 10.1093/ndt/gfp078
- 8. Parfrey PS, Drueke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al.: The Effects
 of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of
 Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. *Clin J Am Soc Nephrol*, 10: 791-799, 2015 10.2215/CJN.07730814
- 9. Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, et al.: Calcification is
 associated with loss of functional calcium-sensing receptor in vascular smooth muscle
 cells. *Cardiovasc Res*, 81: 260-268, 2009 10.1093/cvr/cvn279
- 10. Henaut L, Boudot C, Massy ZA, Lopez-Fernandez I, Dupont S, Mary A, et al.:
 Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth
 muscle cells: mechanisms of action. *Cardiovasc Res*, 101: 256-265, 2014
 10.1093/cvr/cvt249
- 656 11. Ciceri P, Elli F, Brenna I, Volpi E, Brancaccio D, Cozzolino M: The Calcimimetic Calindol
 657 Prevents High Phosphate-Induced Vascular Calcification by Upregulating Matrix GLA
 658 Protein. Nephron Exp Nephrol, 122: 75-82, 2013 10.1159/000349935
- 12. Ciceri P, Volpi E, Brenna I, Elli F, Borghi E, Brancaccio D, et al.: The combination of
 lanthanum chloride and the calcimimetic calindol delays the progression of vascular
 smooth muscle cells calcification. *Biochem Biophys Res Commun*, 418: 770-773, 2012
 10.1016/j.bbrc.2012.01.097
- 13. Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML: A calcimimetic (R-568), but not
 calcitriol, prevents vascular remodeling in uremia. *Kidney Int*, 75: 60-71, 2009
 10.1038/ki.2008.490
- Mendoza FJ, Martinez-Moreno J, Almaden Y, Rodriguez-Ortiz ME, Lopez I, Estepa JC, et
 al.: Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular
 smooth muscle cells. *Calcif Tissue Int*, 88: 169-178, 2011 10.1007/s00223-010-9442-4
- 15. Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, et al.: Extracellular
 calcium-sensing receptor is functionally expressed in human artery. *Am J Physiol Renal Physiol*, 293: F946-955, 2007 10.1152/ajprenal.00474.2006
- 672 16. Babinsky VN, Hannan FM, Youhanna SC, Marechal C, Jadoul M, Devuyst O, et al.:
 673 Association studies of calcium-sensing receptor (CaSR) polymorphisms with serum

- 674 concentrations of glucose and phosphate, and vascular calcification in renal transplant 675 recipients. *PloS one*, 10: e0119459, 2015 10.1371/journal.pone.0119459
- 17. Schepelmann M, Yarova PL, Lopez-Fernandez I, Davies TS, Brennan SC, Edwards PJ, et
 al.: The vascular Ca2+-sensing receptor regulates blood vessel tone and blood pressure.
 Am J Physiol Cell Physiol, 310: C193-204, 2016 10.1152/ajpcell.00248.2015
- 18. Chang W, Tu C, Chen TH, Bikle D, Shoback D: The extracellular calcium-sensing receptor
 (CaSR) is a critical modulator of skeletal development. *Sci Signal*, 1: ra1, 2008
 10.1126/scisignal.1159945
- 19. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, et al.: Smooth
 muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic
 effects of ANP on blood pressure. *Proc Natl Acad Sci U S A*, 99: 7142-7147, 2002
 10.1073/pnas.102650499
- 20. Yarova PL, Stewart AL, Sathish V, Britt RD, Jr., Thompson MA, AP PL, et al.: Calciumsensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in
 allergic asthma. *Science translational medicine*, 7: 284ra260, 2015
 10.1126/scitranslmed.aaa0282
- 690 21. Sage AP, Lu J, Tintut Y, Demer LL: Hyperphosphatemia-induced nanocrystals upregulate
 691 the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth
 692 muscle cells in vitro. *Kidney Int*, 79: 414-422, 2011 10.1038/ki.2010.390
- 693 22. Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image
 694 analysis. *Nat Methods*, 9: 671-675, 2012
- 695 23. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al.: Fiji: an
 696 open-source platform for biological-image analysis. *Nat Methods*, 9: 676-682, 2012
 697 10.1038/nmeth.2019
- 698 24. Sun Y, Yu H, Zheng D, Cao Q, Wang Y, Harris D, et al.: Sudan black B reduces
 699 autofluorescence in murine renal tissue. *Arch Pathol Lab Med*, 135: 1335-1342, 2011
 700 10.5858/arpa.2010-0549-OA
- Puchtler H, Meloan SN, Terry MS: On the history and mechanism of alizarin and alizarin
 red S stains for calcium. *J Histochem Cytochem*, 17: 110-124, 1969
- 26. Jono S, Nishizawa Y, Shioi A, Morii H: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*, 17: 1135-1142, 1997
- 707 27. Moorehead WR, Biggs HG: 2-Amino-2-methyl-1-propanol as the alkalizing agent in an
 708 improved continuous-flow cresolphthalein complexone procedure for calcium in serum.
 709 *Clin Chem*, 20: 1458-1460, 1974
- 28. Leroux-Berger M, Queguiner I, Maciel TT, Ho A, Relaix F, Kempf H: Pathologic
 calcification of adult vascular smooth muscle cells differs on their crest or mesodermal
 embryonic origin. *J Bone Miner Res*, 26: 1543-1553, 2011 10.1002/jbmr.382
- 29. Cheng Z, Liang N, Chen TH, Li A, Santa Maria C, You M, et al.: Sex and age modify
 biochemical and skeletal manifestations of chronic hyperparathyroidism by altering
 target organ responses to Ca2+ and parathyroid hormone in mice. *J Bone Miner Res*,
 28: 1087-1100, 2013 10.1002/jbmr.1846
- 30. Ranieri M, Tamma G, Di Mise A, Russo A, Centrone M, Svelto M, et al.: Negative feedback
 from CaSR signaling to aquaporin-2 sensitizes vasopressin to extracellular Ca2. *Journal of cell science*, 128: 2350-2360, 2015 10.1242/jcs.168096
- 31. Graca JA, Schepelmann M, Brennan SC, Reens J, Chang W, Yan P, et al.: Comparative
 expression of the extracellular calcium-sensing receptor in the mouse, rat, and human
 kidney. *Am J Physiol Renal Physiol*, 310: F518-533, 2016 10.1152/ajprenal.00208.2015
- 32. Tamma G, Lasorsa D, Ranieri M, Mastrofrancesco L, Valenti G, Svelto M: Integrin
 signaling modulates AQP2 trafficking via Arg-Gly-Asp (RGD) motif. *Cellular*

- physiology and biochemistry : international journal of experimental cellular
 physiology, biochemistry, and pharmaco, 27: 739-748, 2011 10.1159/000330082
- 33. Trimpert C, van den Berg DT, Fenton RA, Klussmann E, Deen PM: Vasopressin increases
 S261 phosphorylation in AQP2-P262L, a mutant in recessive nephrogenic diabetes
 insipidus. Nephrology, dialysis, transplantation : official publication of the European
 Dialysis and Transplant Associatio, 27: 4389-4397, 2012 10.1093/ndt/gfs292
- 34. Sadler AM, Bailey SJ: Validation of a refined technique for taking repeated blood samples
 from juvenile and adult mice. *Lab Anim*, 47: 316-319, 2013
 10.1177/0023677213494366
- 35. Procino G, Mastrofrancesco L, Tamma G, Lasorsa DR, Ranieri M, Stringini G, et al.:
 Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal
 concentrating defect in humans. An in vivo and in vitro study. *PloS one*, 7: e33145,
 2012 10.1371/journal.pone.0033145
- 738 36. Tamma G, Di Mise A, Ranieri M, Svelto M, Pisot R, Bilancio G, et al.: A decrease in aquaporin 2 excretion is associated with bed rest induced high calciuria. *J Transl Med*, 12: 133, 2014 10.1186/1479-5876-12-133
- 37. Yarova PL, Stewart AL, Sathish V, Britt RD, Jr., Thompson MA, AP PL, et al.: Calciumsensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in
 allergic asthma. *Sci Transl Med*, 7: 284ra260, 2015 10.1126/scitranslmed.aaa0282
- 38. Alexander RT, Woudenberg-Vrenken TE, Buurman J, Dijkman H, van der Eerden BC, van
 Leeuwen JP, et al.: Klotho prevents renal calcium loss. *J Am Soc Nephrol*, 20: 23712379, 2009 10.1681/ASN.2008121273
- 39. Ranieri M, Zahedi K, Tamma G, Centrone M, Di Mise A, Soleimani M, et al.: CaSR
 signaling down-regulates AQP2 expression via a novel microRNA pathway in pendrin
 and NaCl cotransporter knockout mice. *FASEB J*, 32: 2148-2159, 2018
 10.1096/fj.201700412RR
- 40. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media
 calcification in end-stage renal disease: impact on all-cause and cardiovascular
 mortality. *Nephrol Dial Transplant*, 18: 1731-1740, 2003 10.1093/ndt/gfg414
- Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, et al.: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol*, 39: 695-701, 2002 10.1016/s0735-1097(01)01781-8
- 42. Torremade N, Bozic M, Panizo S, Barrio-Vazquez S, Fernandez-Martin JL, Encinas M, et
 al.: Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an
 Increase of 1alpha-Hydroxylase Expression in Vascular Smooth Muscle Cells. *J Bone Miner Res*, 31: 1865-1876, 2016 10.1002/jbmr.2852
- 43. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al.: Association of
 serum phosphate with vascular and valvular calcification in moderate CKD. *J Am Soc Nephrol*, 20: 381-387, 2009 10.1681/ASN.2008040349
- 44. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, et al.: A mouse model of
 human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.
 Nat Genet, 11: 389-394, 1995 10.1038/ng1295-389
- 45. Chang W, Tu CL, Jean-Alphonse FG, Herberger A, Cheng Z, Hwong J, et al.: PTH
 hypersecretion triggered by a GABAB1 and Ca(2+)-sensing receptor heterocomplex in
 hyperparathyroidism. *Nat Metab*, 2: 243-255, 2020 10.1038/s42255-020-0175-z
- 46. Toka HR, Al-Romaih K, Koshy JM, DiBartolo S, 3rd, Kos CH, Quinn SJ, et al.: Deficiency
 of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent
 hypocalciuria. J Am Soc Nephrol, 23: 1879-1890, 2012 10.1681/ASN.2012030323

- 47. Centeno PP, Herberger A, Mun HC, Tu C, Nemeth EF, Chang W, et al.: Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. *Nat Commun*, 10: 4693, 2019 10.1038/s41467-019-12399-9
- 48. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al.: Circulating FGF-23 is
 regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. *J Biol Chem*,
 280: 2543-2549, 2005 10.1074/jbc.M408903200
- 49. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al.: FGF-23 is a
 potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res*, 19: 429-435, 2004 10.1359/JBMR.0301264
- 50. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al.: Targeted
 ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate
 and vitamin D metabolism. *J Clin Invest*, 113: 561-568, 2004 10.1172/JCI19081
- 51. Dalton GD, Xie J, An SW, Huang CL: New Insights into the Mechanism of Action of
 Soluble Klotho. *Front Endocrinol (Lausanne)*, 8: 323, 2017 10.3389/fendo.2017.00323
- 52. Fan Y, Liu W, Bi R, Densmore MJ, Sato T, Mannstadt M, et al.: Interrelated role of Klotho
 and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid
 hyperplasia. *Proc Natl Acad Sci U S A*, 115: E3749-E3758, 2018
 10.1073/pnas.1717754115
- 53. Yoon J, Liu Z, Lee E, Liu L, Ferre S, Pastor J, et al.: Physiologic Regulation of Systemic
 Klotho Levels by Renal CaSR Signaling in Response to CaSR Ligands and pHo. *J Am Soc Nephrol*, 2021 10.1681/ASN.2021020276
- 54. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al.: Mutation of
 the mouse klotho gene leads to a syndrome resembling ageing. *Nature*, 390: 45-51, 1997
 10.1038/36285
- 55. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, et al.: Klotho deficiency causes
 vascular calcification in chronic kidney disease. *J Am Soc Nephrol*, 22: 124-136, 2011
 10.1681/ASN.2009121311
- 56. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al.: Serum FGF23
 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular
 pathology. *Clin J Am Soc Nephrol*, 8: 781-786, 2013 10.2215/CJN.09570912
- 57. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al.: FGF23 induces left
 ventricular hypertrophy. *J Clin Invest*, 121: 4393-4408, 2011 10.1172/JCI46122
- S8. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al.: FGF23
 regulates renal sodium handling and blood pressure. *EMBO Mol Med*, 6: 744-759, 2014
 10.1002/emmm.201303716
- Subramanya AR, Ellison DH: Distal convoluted tubule. *Clin J Am Soc Nephrol*, 9: 2147-2163, 2014 10.2215/CJN.05920613
- 60. de Rouffignac C, Quamme G: Renal magnesium handling and its hormonal control. *Physiol Rev*, 74: 305-322, 1994 10.1152/physrev.1994.74.2.305
- 813 61. Renkema KY, Velic A, Dijkman HB, Verkaart S, van der Kemp AW, Nowik M, et al.: The
 814 calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis. *JAm*815 Soc Nephrol, 20: 1705-1713, 2009 10.1681/ASN.2008111195
- 816 62. Ranieri M: Renal Ca(2+) and Water Handling in Response to Calcium Sensing Receptor
 817 Signaling: Physiopathological Aspects and Role of CaSR-Regulated microRNAs. *Int J* 818 *Mol Sci*, 20, 2019 10.3390/ijms20215341
- 63. Sands JM, Naruse M, Baum M, Jo I, Hebert SC, Brown EM, et al.: Apical extracellular
 calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water
 permeability in rat kidney inner medullary collecting duct. *J Clin Invest*, 99: 1399-1405,
 1997 10.1172/JCI119299

- 823 64. Riccardi D, Brown EM: Physiology and pathophysiology of the calcium-sensing receptor F485-499, 824 Physiol Renal Physiol, 298: 2010 in the kidney. Am J825 10.1152/ajprenal.00608.2009
- 826 65. Brown EM: Physiology and pathophysiology of the extracellular calcium-sensing receptor.
 827 Am J Med, 106: 238-253, 1999
- 66. Molostvov G, Hiemstra TF, Fletcher S, Bland R, Zehnder D: Arterial Expression of the
 Calcium-Sensing Receptor Is Maintained by Physiological Pulsation and Protects
 against Calcification. *PloS one*, 10: e0138833, 2015 10.1371/journal.pone.0138833
- 67. Gosmanova EO, Kovesdy CP: Blood Pressure Targets in CKD: Lessons Learned from
 SPRINT and Previous Observational Studies. *Curr Cardiol Rep*, 18: 88, 2016
 10.1007/s11886-016-0769-y
- 68. Kaludjerovic J, Komaba H, Lanske B: Effects of klotho deletion from bone during chronic
 kidney disease. *Bone*, 100: 50-55, 2017 10.1016/j.bone.2017.02.006
- 836

838 Supplemental Material Table of Contents

840 Page numbers refer to the *supplemental material_revised.pdf*

Table S1	Pg. 2
Table S2	Pg. 3
Figure S1	Pg. 4
Figure S2	Pg. 5
Figure S3	Pg. 6
Figure S4	Pg. 7
Figure S5	Pg. 8
Figure S6	Pg. 9
Figure S7	Pg. 10
Figure S8	Pg. 11

843 Tables

Table 1: Blood biochemistry of 3-month-old WT and KO mice. 1,25-D₃ = 1,25-dihydroxy

845 vitamin D / calcitriol, BUN = blood urea nitrogen. * p < 0.05, ** p < 0.01, *** p < 0.001, mean

846 \pm SD, two-tailed T-test.

Parameter	Parameter Unit WT		Ν	КО	Ν	<i>p</i> -value
Na ⁺	mmol / l	145.35 ± 2.77	17	144.15 ± 3.84	10	0.3540
Cl ⁻	mmol / l	109.18 ± 3.34	17	108.45 ± 4.82	10	0.6472
K ⁺	mmol / l	5.24 ± 0.40	3	5.62 ± 0.18	3	0.2092
Ca ²⁺	mmol / 1	2.28 ± 0.21	28	2.94 ± 0.59	21	<0.0001 ***
Mg ²⁺	mmol / 1	1.06 ± 0.12	22	1.15 ± 0.22	20	0.0979
FGF23	pg / ml	145.0 ± 36.4	11	384.4 ± 204.5	6	0.0015 **
Pi	mmol / 1	2.36 ± 0.45	17	1.94 ± 0.47	16	0.0146 *
Hematocrit	%	40.3 ± 7.6	9	38.9 ± 8.6	6	0.7407
PTH	pg / ml	151.7 ± 115.5	30	256.6 ± 249.8	30	0.0411 *
1,25-D ₃	pmol / 1	162.1 ± 81.3	19	310.8 ± 173.4	17	0.0020 **
α-Klotho	pg / ml	555.4 ± 164.6	13	564.7 ± 389.3	11	0.9379
Aldosterone	pg / ml	508.1 ± 199.0	12	421.8 ± 205.2	12	0.3072
Renin	pg / ml	123.8 ± 58.0	12	115.4 ± 40.3	12	0.6850
Fetuin A	µg / ml	201.4 ± 40.9	12	193.0 ± 40.8	12	0.6175
PPi	µmol / 1	34.1 ± 40.8	12	25.0 ± 14.2	12	0.4747
Albumin	mg / ml	29.4 ± 1.4	11	27.6 ± 1.7	11	0.0179 *
ALP	U/1	81.73 ± 11.38	11	100.18 ± 22.74	11	0.0297 *
Creatinine	µmol / 1	15.4 ± 1.6	6	13.0 ± 1.3	5	0.0265 *
Urea	mmol / 1	10.1 ± 1.3	6	10.4 ± 0.3	5	0.6474
BUN	mmol / 1	8.4 ± 2.4	11	8.7 ± 1.8	11	0.7781
Total Protein	mg / ml	54.4 ± 3.0	6	51.2 ± 2.6	4	0.1196

847

849	Table 2: Urine chemistry of 3-month-old WT and KO mice. Averages of measurements
850	from two consecutive 24 h urine collections. $Cr = creatinine$, $d = 24$ h, $BW = body$ weight (g),
851	Na ⁺ , Cl ⁻ , K ⁺ , Ca ²⁺ , Mg ²⁺ , and Pi are normalised to individual creatinine levels of each mouse.
852	Creatinine, total urinary protein, urea, uric acid, and glucose are normalised to 24 h urine
853	production per bodyweight of each mouse. * $p < 0.05$, *** $p < 0.001$, mean ± SD, two-tailed
854	T-test.

Parameter	Unit		WT		Ν		ко		Ν	<i>p</i> -value	
Na ⁺ :Cr	mmol / mmol	37.32	±	9.93	6	34.06	±	12.57	6	0.6290	
Cl ⁻ :Cr	mmol / mmol	70.18	±	10.93	6	69.25	±	19.70	6	0.9215	
K+:Cr	mmol / mmol	50.25	±	9.27	6	58.62	±	8.86	6	0.1410	
Ca ²⁺ :Cr	mmol / mmol	0.90	±	0.55	6	6.48	±	4.56	6	0.0140	*
Mg ²⁺ :Cr	mmol / mmol	6.40	±	1.81	4	8.05	±	3.19	3	0.4184	
Pi:Cr	mmol / mmol	7.84	±	2.98	6	22.45	±	5.92	6	0.0003	***
Cr	µmol / (d * BW)	0.230	±	0.038	6	0.221	±	0.061	6	0.7548	
Total protein	µg / (d * BW)	197.43	±	112.49	6	176.34	±	104.42	6	0.7435	
Urea	µmol / (d * BW)	80.23	±	21.42	6	80.42	±	19.88	6	0.9876	
Uric acid	μ mol / (d * BW)	37.33	±	8.20	6	32.30	±	11.60	6	0.4069	
Glucose	μ mol / (d * BW)	0.133	±	0.030	6	0.219	±	0.178	6	0.2694	
24h urine	mg / h / BW	2.50	±	0.56	6	2.98	±	0.60	5	0.1999	

858	Table 3: Results of μ CT analysis of hind-leg bones from 3-month-old WT and KO mice.
859	Bone parameter abbreviations: $Tb = trabecular$ bone at the distal femur, $Ct = cortical$ bone at
860	the tibio-fibular junction, $TV = total volume$, $BV = bone volume$, $BV/TV = bone volume$
861	fraction, CD = connectivity density, SMI = structure model index, N = trabecular number, Th
862	= thickness, Sp = spacing, BMD = bone mineral density. AU = arbitrary units. Mean \pm SD, * p
863	< 0.05, ** $p < 0.01$, two-tailed Student's t-test.

Parameter	Unit	V	VT	Ν		ко		Ν	<i>p</i> -value	
Tb.TV	mm ³	2.13	± 0.25	8	1.88	±	0.15	9	0.0238	*
Tb.BV	mm ³	0.33	± 0,05	8	0.24	±	0.04	9	0.0014	**
Tb.BV/TV	ratio	0.16	± 0.02	8	0.13	±	0.02	9	0.0133	*
Tb.CD	1/mm ³	369.62	± 39.79	8	285.25	±	49.53	9	0.0016	**
Tb.SMI	AU	2.07	± 0.28	8	2.37	±	0.15	9	0.0123	*
Tb.N	1/mm ³	5.91	± 0.42	8	5.08	±	0.80	9	0.0189	*
Tb.Th	μm	39.09	± 5.94	8	37.30	±	4.49	9	0.4915	
Tb.Sp	mm	0.17	± 0.01	8	0.19	±	0.02	9	0.0140	*
Tb.BMD	AU	1164.85	± 8.75	8	1138.54	±	23.69	9	0.0098	**
Ct.TV	mm ³	0.40	± 0.03	8	0.39	±	0.04	9	0.3678	
Ct.BV	mm ³	0.27	± 0.02	8	0.25	±	0.03	9	0.1977	
Ct.BV/TV	ratio	0.66	± 0.03	8	0.66	±	0.03	9	0.5431	
Ct.BMD	AU	1433.39	± 33.25	8	1394.06	±	16.96	9	0.0069	**
Ct.Th	μm	235.13	± 15.15	8	226.56	±	13.38	9	0.2344	

867 Table 4: Comparison of the Klotho^{-/-}, PTG-CaSR^{-/-}, Renal-CaSR^{-/-} and VSMC-CaSR^{-/-}

868 **mice.** Arrows: (fold changes compared to control animals) =: no change, 1-2: \downarrow/\uparrow ; 2-3: $\downarrow\downarrow/\uparrow\uparrow$;

Parameter	Klotho deficient 54, 68	PTG-CaSR -/- 18	Renal-CaSR ^{-/- 46}	VSMC-CaSR ^{-/-}
Plasma Ca ²⁺	↑	↑ ↑	=	↑
Urinary Ca ²⁺	n.d.	$\uparrow \uparrow \uparrow$	$\downarrow\downarrow\downarrow\downarrow$	$\uparrow\uparrow\uparrow$
Plasma Pi	↑ (n.d.	=	\downarrow
Urinary Pi	↑ (n.d.	n.d.	$\uparrow \uparrow$
Plasma 1,25-D ₃	$\uparrow \uparrow$	n.d.	=	$\uparrow \uparrow$
Plasma PTH	\downarrow	$\uparrow \uparrow \uparrow$	=	↑
FGF23	↑ ↑	n.d.	n.d.	$\uparrow \uparrow$
Body weight	$\downarrow\downarrow$	$\downarrow\downarrow\downarrow\downarrow$	=	=/↓
BMD	Ļ	$\downarrow\downarrow\downarrow\downarrow$	=	\downarrow

869 >3: $\downarrow \downarrow \downarrow \uparrow \uparrow \uparrow$, n.d.: not determined

870

871 Figure legends

872 Figure 1: In vitro calcification of isolated VSMC. A: Photograph of 24-well microplates with 873 cultured VSMC from WT (left two plates) and KO mouse aortas (right two plates) incubated for 10 days with a series of Ca²⁺ (numbers: mM Ca²⁺ in the 3 horizontally adjacent wells) / 874 875 phosphate (Pi) concentrations (top two plates: 2 mM Pi, bottom two plates: 3 mM Pi) in the 876 growth medium. Cells were then fixed and stained with Alizarin Red S. Darker spots indicate calcium deposits. At 2 mM Pi, WT did not show any calcification independent of the Ca²⁺ 877 concentration, while VSMC from KO mice started to show calcification at 1.6 mM Ca²⁺. At 3 878 mM Pi, WT cells started to calcify at 1.6 mM Ca²⁺ and KO cells at 1.2 mM Ca²⁺. B: 879 Quantification of Ca²⁺ deposition in WT and KO cells at 3 mM Pi and 1.2, 1.8 or 2.5 mM Ca²⁺ 880 881 using o-cresolphthalein complexone assay, normalised to the amount of protein (BCA assay) and the normocalcemic (1.2 mM Ca^{2+}) control. Friedmann with Dunn post-hoc test. C: 882 Quantification of Ca²⁺ deposition in WT and KO cells at 3 mM Pi and 1.2 mM Ca²⁺ in the 883 presence or absence of 10 nM calcimimetic R-568. Median±IQR, Mann-Whitney-U test. * p < 884 0.05, ** p < 0.01.885

886

Figure 2: Aorta mRNA expression levels and quantitative immunohistochemistry. A: 887 888 Klotho, **B**: Cyp27b1, and **C**: Sm22 α mRNA expression levels relative to calibrator (mean Δ CT 889 WT). D & E: quantitative immunohistochemistry analysis of α-Klotho in smooth muscle and 890 endothelial layer of WT and KO aorta sections. Mean grey values (lower = darker). F: 891 representative stainings for α -Klotho used for quantification. G & H: quantitative 892 immunohistochemistry analysis of CYP27B1 in smooth muscle and endothelial layer of WT 893 and KO aorta sections. Mean grey values (lower = darker). I: representative stainings for 894 CYP27B1 used for quantification. Inserts = IgG negative control. Inserts = IgG negative 895 control. Scale bars = $50 \,\mu m$.

896

Figure 3: Kidney calcium handling and CaSR expression in ^{SM22α}CaSR^{Δflox/Δflox} mice. A-B: 897 898 semi-quantitative Western blot analyses of \Box -Klotho and the sodium phosphate cotransporter, 899 NaPi2a. C-F: quantitative immunohistochemistry of the vitamin D receptor (VDR), the calcium 900 channel Transient Receptor Potential cation channel subfamily V member 5 (TRPV5), 901 calbindin (D28K) and the plasma membrane calcium ATPase (PMCA). G: CaSR mRNA 902 expression in whole kidney lysate relative to calibrator (mean ΔCT of WT). H: quantitative 903 immunofluorescence analysis of CaSR expression in kidney sections. I: semi-quantitative Western blot analysis of CaSR protein expression in whole kidney lysates. Mean \pm SD, * $p \leq$ 904 905 0.05, ** p < 0.01, *** p < 0.001, two-tailed Student's t-test.

906


Figure 4: Kidney water transport in SM22a CaSR^{Aflox/Aflox} mice. A: Optical microscopy images 907 908 of crystal precipitates in urines from WT and KO mice (scale bar: 100 µm). B: Urine osmolality 909 and C: urine pH of WT and KO mice from two consecutive days in metabolic cages. Mean±SD, ** p < 0.01, *** p < 0.001 for overall genotype effect, two-way ANOVA. **D-H:** semi-910 911 quantitative Western blot analyses of the thiazide sensitive sodium-chloride cotransporter 912 (NCC), V-H⁺-ATPase, total aquaporin 2 (AQP2), pS261-AQP2, pS256-AQP2 in WT and KO 913 kidney lysates. I: AQP2 excretion measured by ELISA assay in urines from WT and KO. 914 Mean \pm SD, * p < 0.05, ** p < 0.01, two-tailed Student's t-test.


915


Figure 5: **Analysis of the parathyroid glands. A**: Micrographs of isolated parathyroid glands from WT and KO mice. Scale bar = 500 μ m. **B**: Immunofluorescence images of isolated parathyroid glands from WT and KO mice, showing comparable staining intensity for the CaSR. Scale bar = 50 μ m. **C**: Western Blot analysis of CaSR expression in parathyroid glands, showing equal expression of both the monomer (~130 kDa) and the dimer (~250 kDa) of the CaSR. **D**: PTH release assay in response to increases in extracellular Ca²⁺. Left panel: raw data, right panel: normalised to PTH release at 0.5 mM $Ca^{2+} = 100 \%$ for both WT and KO. Vertical lines indicate Ca^{2+} concentration at half maximal PTH response. N = 3, < 1.4 % total variance explained by genotype as determined by repeated measures two-way ANOVA.


925


Figure 6: Phenotype of the SM22aCaSR $\Delta flox/\Delta flox$ mice. Continuous lines = stimulation, broken 926 927 lines = inhibition. Greved out lines = loss of action due to VSMC-CaSR deletion. 928 Loss of the CaSR in VSMC affects whole body mineral ion homeostasis leading to the loss 929 (red X signs) of an inhibitory function on the production / secretion of 1,25-D₃, PTH, and 930 FGF23. At the same time, VSMC-CaSR loss apparently also affects or overrides hormonal 931 control: 1,25-D3 synthesis is apparently resistant to control by FGF23, while PTH secretion is 932 (slightly) increased, pointing to some degree of resistance to control by 1,25-D₃, FGF23, and 933 serum calcium (despite a fully functional CaSR in the parathyroid glands). The increased 934 1,25-D₃ and PTH leads to hypercalcemia followed by hypercalciuria. Pi excretion is increased 935 as a result of the increased PTH and FGF23 levels, leading to low serum Pi. Urine osmolality 936 and pH are decreased to prevent nephrolithiasis. The urinary calcium and phosphate wasting 937 then contributes to the observed bone loss in these animals (not shown in the scheme). Owing 938 to the presence of blood vessels in all organs of the body, it remains to be elucidated whether 939 all the observed features of this phenotype are primary to CaSR deletion from the VSMC, 940 secondary compensatory mechanisms, or a combination of both.




















Supplemental material

Table of contents

Table S1	Pg. 2
Table S2	Pg. 3
Figure S1	Pg. 4
Figure S2	Pg. 5
Figure S3	Pg. 6
Figure S4	Pg. 7
Figure S5	Pg. 8
Figure S6	Pg. 9
Figure S7	Pg. 10
Figure S8	Pg. 11

Table S1: Blood biochemistry of 18-month-old WT and KO mouse. * $p < 0.05$, ** $p < 0.01$,
mean \pm SD, two-tailed T-test. "CaSR" indicates concentration of N-terminal soluble CaSR /
CaSR-fragment. Osmolality and CaSR were measured in male and female mice.

Parameter	Unit	WT	Ν	КО	Ν	<i>p</i> -value
Na ⁺	mmol / l	149.0 ± 3.61	3	146.3 ± 3.06	3	0.3837
K^+	mmol/l	10.64 ± 0.61	3	11.88 ± 2.53	3	0.4541
Cl	mmol / 1	114.33 ± 1.15	3	111.00 ± 3.61	3	0.2020
Ca ²⁺	mmol / 1	2.34 ± 0.13	3	2.99 ± 0.35	3	0.0401 *
Mg ²⁺	mmol / l	1.65 ± 0.18	3	2.04 ± 0.33	3	0.1369
FGF23	pg / ml	131.1 ± 45.5	3	330.0 ± 49.7	3	0.0069 **
α-Klotho	pg / ml	2005.9 ± 1342.1	4	1873.0 ± 1016.5	4	0.8797
Osmolality	mosmol/kg	289.2 ± 11.7	5	288.1 ± 5.6	7	0.8369
CaSR	ng / ml	2.17 ± 0.98	5	2.03 ± 0.78	7	0.7816

Table S2: Organ weights of 6 and 18-month-old animals. WT vs. KO, mean ± SD, two-tailed

T-test.

Organ	Unit	WT	Ν	КО	Ν	<i>p</i> -value	
Kidney	mg	235.0 ± 32.3	7	232.9 ± 23.8	7	0.8899	
Liver	mg	1332.2 ± 134.2	8	1445.6 ± 190.9	7	0.2016	
Stomach	mg	339.4 ± 86.8	8	444.6 ± 256.8	7	0.2938	
Spleen	mg	88.1 ± 31.3	8	99.1 ± 34.3	6	0.5467	
Heart	mg	148.8 ± 31.0	8	145.4 ± 17.7	6	0.8144	
18-month-old animals							
Kidney	mg	313.1 ± 37.6	6	313.0 ± 12.9	4	0.9950	
Liver	mg	2294.1 ± 461.2	6	2399.8 ± 107.9	4	0.6703	
Stomach	mg	846.8 ± 372.0	6	738.8 ± 247.6	4	0.6268	
Spleen	mg	129.1 ± 52.6	6	101.6 ± 24.8	4	0.3637	
Heart	mg	201.8 ± 20.4	5	231.9 ± 8.4	4	0.0285 *	

6-month-old animals



Figure S1: Generation of explant derived aortic VSMC. A: The thoracic aorta is dissected from the spine and **B:** removed to a Petri dish filled with sterile isolation medium where **C and D:** the vessel is cleared from tunica adventitia by gently pulling / scraping the connective tissue until **E:** only the semi-translucent tunica media remains. **F:** The vessel is then cut into small (ca. 1 mm) pieces that are then **G:** transferred into a T-25 cell culture flask by the use of a hypodermic needle. **H:** The flask is kept in an upright position at 37 °C for 10–15 minutes so that the explants are not in contact with medium and can attach firmly to the surface of the flask. 5 ml isolation medium is added, and the explants are kept at 37 °C / 95 % relative humidity (rh) / 5 % CO2 for ca. 7 days after which the medium is changed. **I:** VSMC will start to grow out of the explants. **J:** After ca. 2-3 weeks, the explants are removed and the VSMC passaged to generate a monolayer of cells.




Figure S2: *Ex vivo* **aortic calcification.** Graph: Quantification of Ca^{2+} deposition in WT and KO aortas or 3-month-old mice. Mean±SD. Pictures: Alizarin Red S stainings of thoracic aorta sections from 12-month-old WT and KO animals incubated for 10 days in the presence of medium containing 1.8 mM Ca²⁺ and 3 mM Pi.




Figure S3: Metabolic cage studies of WT and KO mice. A. Food intake, **B**: Water intake, **C**: Feces excretion, **D**: Urine excretion. Data are shown as consumption (in mg) per h per g bodyweight. Mean±SD.






Figure S4: **Supplemental kidney mRNA and protein expression. A**: *Cyp27b1*, and **B**: *Aqp2* mRNA expression levels relative to calibrator (mean ΔCT WT). Representative Western blots showing **C**: Klotho, **D**: NaPi2a, **E**: NCC, **F**: AQP2 expression in kidneys from WT and KO mice.



200 µm

Figure S5: Immunohistochemistry stainings of Cyp27b1 in kidneys of WT and KO mice. Stainings were performed as described in the methods section for Cyp27b1 using the LSBio (Seattle, USA) rabbit anti-Cyp27b1 antibody at 1:1000 dilution. **A:** Overview of representative whole kidney sections stained for Cyp27b1. Insert: negative control. **B:** Cortex of N=4 WT and KO kidneys stained for Cyp27b1 and respective negative controls.






Figure S6: Supplemental kidney CaSR expression data and representative images from Figure 3. A: immunohistochemistry of CaSR expression pattern in WT and KO kidney sections. Scale bar = 1 mm. B: immunofluorescence analysis of CaSR expression levels in WT and KO kidneys used for quantitative immunofluorescence analysis. Scale bar = 200 μ m. C: representative Western blot for CaSR in the kidney (~120-150 kDa: monomer; 250 kDa: dimer).




Figure S7: Plasma levels of bone metabolism markers procollagen type 1 (P1NP) and Tartrate-resistant acid phosphatase 5b (TRAcP5b), Fgf23 mRNA expression in bone, and μ CT. Bone metabolism markers: * p < 0.05, two tailed T-test; measured in male and female mice. RT-qPCR: * p < 0.05, Mann-Whitney test. μ CT: representative 2-dimension (2D) radiographs and 3-dimension (3D) reconstructed images from distal femures of 3 months old KO and WT (control) littermates. The 2D radiographs were taken 100 μ m below the growth plate. Scale bar: 400 μ m




Figure S8: Serum levels of "soluble" CaSR / CaSR fragment. N = 5 (WT, 18 months), N = 7 (KO, 18 months), N = 3 (WT, 3 months), and N = 3 (KO, 3 months). Three of the 3-month samples, (2 WT, 1 KO) were below the detection range and are thus not included in the graph. An additional serum sample of a genetically non-modified 14 month-old mouse ("Ctrl") was added for reference, which had a comparable level of CaSR in the serum. Finally, a sample of 100 mg / ml kidney lysate from a genetically non-modified mouse was tested as positive control.